Table 1.
Summary of patient disposition from Study 1 and Study 2—all randomized patients
| Study 1a | Study 2b | |||||
|---|---|---|---|---|---|---|
|
NEPA (N = 726) (C = 2983) |
PALO (N = 729) (C = 2986) |
Overall (N = 1455) (C = 5969) |
NEPA (N = 309) (C = 1446) |
APR‐PALO (N = 104) (C = 515) |
Overall (N = 413) (C = 1961) |
|
| Treated, n (%) | 724 (99.7) | 726 (99.6) | 1450 (99.7) | 309 (100.0) | 103 (99.0) | 412 (99.8) |
| Completed cycle 1, n (%) | 719 (99.0) | 719 (98.6) | 1438 (98.8) | 303 (98.1) | 102 (98.1) | 405 (98.1) |
| Completed cycle 2, n (%) | 630 (86.8) | 645 (88.5) | 1275 (87.6) | 278 (90.0) | 94 (90.4) | 372 (90.1) |
| Completed cycle 3, n (%) | 596 (82.1) | 603 (82.7) | 1199 (82.4) | 255 (82.5) | 88 (84.6) | 343 (83.1) |
| Completed cycle 4, n (%) | 548 (75.5) | 559 (76.7) | 1107 (76.1) | 230 (74.4) | 81 (77.9) | 311 (75.3) |
C = Total number of cycles started for all treated patients.
APR, aprepitant; NEPA, netupitant‐palonosetron; PALO, palonosetron.
a
Data corresponding to cycles 5‐8 not shown.
b
Data corresponding to cycles 5‐14 not shown.